標(biāo)題: Titlebook: Biomarkers in Cancer; Victor R. Preedy,Vinood B. Patel Reference work 2015 Springer Science+Business Media Dordrecht 2015 Application to p [打印本頁] 作者: 烹飪 時(shí)間: 2025-3-21 19:38
書目名稱Biomarkers in Cancer影響因子(影響力)
書目名稱Biomarkers in Cancer影響因子(影響力)學(xué)科排名
書目名稱Biomarkers in Cancer網(wǎng)絡(luò)公開度
書目名稱Biomarkers in Cancer網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biomarkers in Cancer被引頻次
書目名稱Biomarkers in Cancer被引頻次學(xué)科排名
書目名稱Biomarkers in Cancer年度引用
書目名稱Biomarkers in Cancer年度引用學(xué)科排名
書目名稱Biomarkers in Cancer讀者反饋
書目名稱Biomarkers in Cancer讀者反饋學(xué)科排名
作者: Intentional 時(shí)間: 2025-3-21 21:13
Forschungsstand zur Europ?isierungmerging blood-based molecular biomarkers that have been evaluated for the detection and monitoring of lung cancer. We specially focus on biomarkers based on a non-invasive liquid biopsy approach, such as circulating tumor cells (CTCs), circulating miRNAs, gene promoter methylation, and DNA mutations in cell-free circulating DNA.作者: GUEER 時(shí)間: 2025-3-22 03:22
Epigenetics and Biomarkers in Lung Cancer: Emerging Blood-Based Molecular Biomarkers for Detection amerging blood-based molecular biomarkers that have been evaluated for the detection and monitoring of lung cancer. We specially focus on biomarkers based on a non-invasive liquid biopsy approach, such as circulating tumor cells (CTCs), circulating miRNAs, gene promoter methylation, and DNA mutations in cell-free circulating DNA.作者: 瑣碎 時(shí)間: 2025-3-22 08:35 作者: inflate 時(shí)間: 2025-3-22 12:19 作者: CHAFE 時(shí)間: 2025-3-22 13:12 作者: 管理員 時(shí)間: 2025-3-22 17:27
DNA Methylation as a Biomarker in Cancer in comparison with others, and their status in applications of DNA methylation biomarkers in cancer. The research field of DNA methylation biomarking is evolving rapidly with promising results that have the potential to confer enormous benefits for cancer patients in the future.作者: atopic 時(shí)間: 2025-3-22 22:30 作者: 莎草 時(shí)間: 2025-3-23 04:31
Konfliktmanagement im Unternehmennce of KLKs. KLK members have been proposed as tissue and/or serological biomarkers for early diagnosis, effective prognosis, and treatment monitoring of cancer patients. This chapter presents an overview of the current knowledge concerning the immense potential of KLKs as biomarkers in human malignancies.作者: 占卜者 時(shí)間: 2025-3-23 08:07
Forschungsstand zur Europ?isierungassociated with higher metastasis risk and poor outcome. Complete and standardized methods to study maspin are necessary in order to evaluate its therapeutic implications and to understand how different subcellular distributions and epigenetic alterations could be helpful for a shared interpretation of results.作者: NEX 時(shí)間: 2025-3-23 09:41 作者: STEER 時(shí)間: 2025-3-23 17:43
Maspin Staining and Its Use as Biomarker in Lung Cancerassociated with higher metastasis risk and poor outcome. Complete and standardized methods to study maspin are necessary in order to evaluate its therapeutic implications and to understand how different subcellular distributions and epigenetic alterations could be helpful for a shared interpretation of results.作者: V切開 時(shí)間: 2025-3-23 20:20 作者: neoplasm 時(shí)間: 2025-3-23 22:51
http://image.papertrans.cn/b/image/187805.jpg作者: 破裂 時(shí)間: 2025-3-24 03:49
,Willkommen auf der Security-Bühne,usually based on genome information. Main sections of OMICS sciences include transcriptomics, proteomics, and metabolomics, powerful research instruments capable of high-throughput detection of biomolecules differentially expressed between tumor and non-tumor samples, including excised tissues or bi作者: Kaleidoscope 時(shí)間: 2025-3-24 09:48
,Willkommen auf der Security-Bühne,iciently sensitive to detect very rare cells, there has been a considerable increase in research to improve detection of CTCs. Here we discuss the current technologies employed for the enumeration and characterization of CTCs. The implementation of such technologies has enabled research into determi作者: 減震 時(shí)間: 2025-3-24 11:40 作者: indemnify 時(shí)間: 2025-3-24 18:51
Konfliktmanagement im Unternehmens, in particular involving heart function. This particular form of cardiotoxicity is related to many factors: age, cumulative dose of the drug administered, drug combination, smoking, prior radiotherapy, and prior cardiovascular disease. Different types of events may manifest: the more important and作者: saphenous-vein 時(shí)間: 2025-3-24 21:04
https://doi.org/10.1007/978-3-642-35689-6at is easily detectable in clinical specimens such as blood, sputum, urine, and stool, DNA methylation alterations in tumorigeneses have become one of the promising candidate biomarkers for early detection, prognosis, therapeutic response prediction, and recurrence monitoring in cancer patients. Rec作者: 無能的人 時(shí)間: 2025-3-25 01:35
Konfliktmanagement im Unternehmenlling a plethora of physiological functions. During the past few years, the KLK family members have drawn a constantly increasing attention regarding their biomarker capabilities. The frequently observed deregulated KLK expression patterns in human malignancies, along with their active involvement i作者: ARM 時(shí)間: 2025-3-25 03:19 作者: 瘙癢 時(shí)間: 2025-3-25 10:56
Grundlagen und Ausgangssituation,the diagnosis and monitoring of disease in a number of different cancers. Serum carbohydrate antigen 19-9 (CA 19-9) is a biomarker that found utility mainly in biliary tract and pancreatic malignancies as a prognostic marker in monitoring response to treatment and as an indication of disease recurre作者: aristocracy 時(shí)間: 2025-3-25 13:35
https://doi.org/10.1007/978-3-663-13253-0l rat pituitary tissue. It was rapidly recognized that PTTG mRNA and protein are much more abundant in various human tumor types as compared to the corresponding non-tumor tissue. The mammalian PTTG protein was found to be a securin, required for correct sister-chromatid separation and equal distrib作者: 充氣球 時(shí)間: 2025-3-25 17:53 作者: 百靈鳥 時(shí)間: 2025-3-25 20:02
https://doi.org/10.1007/978-3-658-26534-2 summarizes recent urine biomarker developments; and details their implications for prognosis and decision making in non-muscle-invasive bladder cancer (NMIBC). Several urine biomarkers have been reported as FDA-approved adjunctive tests for use in the initial diagnosis of bladder cancer and surveil作者: 懶惰人民 時(shí)間: 2025-3-26 00:12
https://doi.org/10.1007/978-3-322-94166-4CC exist, many tumors are accidentally detected, and clinical decision-making is still mainly based on morphological evaluation. Being a relatively chemotherapeutic-resistant and very heterogenic disease, the biological behavior of this tumor type is difficult to predict. Histologic subtyping, tumor作者: 半圓鑿 時(shí)間: 2025-3-26 08:00 作者: lymphedema 時(shí)間: 2025-3-26 11:39 作者: 和諧 時(shí)間: 2025-3-26 15:32 作者: Obstacle 時(shí)間: 2025-3-26 16:52 作者: 虛度 時(shí)間: 2025-3-26 22:25
https://doi.org/10.1007/978-94-007-7681-4Application to prognosis; Biomarkers in disease; Cancer Research; Discovery of biomarkers; High throughp作者: 大約冬季 時(shí)間: 2025-3-27 04:30 作者: FELON 時(shí)間: 2025-3-27 05:59
,Willkommen auf der Security-Bühne,th a certain cancer, RNA or protein biomarker signatures may help to select a specific therapy or to predict the probability of a relapse. A number of clinically relevant, validated, and approved signatures of RNA and protein analytes successfully emerged from OMICS pipelines. It is important to rem作者: fatty-streak 時(shí)間: 2025-3-27 11:46
,Willkommen auf der Security-Bühne,aggressive adjuvant therapy. Furthermore, various studies have shown that temporal monitoring of CTCs can be used to evaluate patient responses to therapy and to detect genetic and phenotypic changes to tumors in real time, allowing more effective treatment guidance.作者: Hot-Flash 時(shí)間: 2025-3-27 16:42 作者: 充滿裝飾 時(shí)間: 2025-3-27 19:58
Konfliktmanagement im Unternehmenike targeted therapy (i.e., trastuzumab) or angiogenesis inhibitors are all associated with some form of cardiac toxicity: while targeted drugs may induce a reversible damage, angiogenesis inhibitors have a prothrombotic activity, which leads to a high incidence of thromboembolic events..Patients we作者: 平項(xiàng)山 時(shí)間: 2025-3-28 00:46 作者: 遠(yuǎn)足 時(shí)間: 2025-3-28 04:08 作者: 文字 時(shí)間: 2025-3-28 09:30
https://doi.org/10.1007/978-3-663-13253-0, and to p53, which is of major importance for cell cycle regulation and apoptosis. Among the PTTG-regulated genes are some which are associated with tumor cell migration and invasion, corresponding to the metastasis-enhancing function of PTTG observed in xenograft models. In several human tumor typ作者: frenzy 時(shí)間: 2025-3-28 13:49
Konfliktmanagement und Unternehmenserfolgd levels among others in the blood of patients suffering from pancreatic, colorectal, and non-small-cell lung cancer as compared to noncancerous controls. Sensitivity and specificity levels reached with the proposed U2 snRNA fragment detection assays were well above the levels reported for current n作者: 保守 時(shí)間: 2025-3-28 14:49
https://doi.org/10.1007/978-3-658-26534-2and Ki-67 (MIB-1) overexpression and UroVysion (multicolor fluorescence in situ hybridization kit for detecting copy number aberrations in chromosomes 3, 7, and 17, and the 9p21 locus), are promising for predicting disease progression and tumor recurrence in NMIBC. Further validation with a prospect作者: 腫塊 時(shí)間: 2025-3-28 22:23
https://doi.org/10.1007/978-3-322-94166-4 identify biomarkers in RCC. As a result, a large number of such markers, including pathways and gene signatures, have been described as promising biomarkers with significant prognostic and predictive value. However, at present and in contrast to other tumor types such as breast cancer, lung cancer,作者: 包庇 時(shí)間: 2025-3-28 22:56
https://doi.org/10.1007/978-3-322-94166-4disease. Further, we report on their relevance as serum biomarkers for the diagnosis, estimation of prognosis, as well as the prediction and monitoring of response to cytotoxic therapy in cancer patients.作者: Inflated 時(shí)間: 2025-3-29 05:06
Konfliktregelung durch Europ?isierunggh inadequate choices of therapeutics for glioma patients currently make biomarkers’ utility for glioma patients limited, recent advances are shedding light not only on the heterogeneity of glioma tumors within and across the subtypes, but also on the heterogeneity between malignant cells within the作者: inundate 時(shí)間: 2025-3-29 08:13
OMICS for Tumor Biomarker Researchth a certain cancer, RNA or protein biomarker signatures may help to select a specific therapy or to predict the probability of a relapse. A number of clinically relevant, validated, and approved signatures of RNA and protein analytes successfully emerged from OMICS pipelines. It is important to rem作者: BALE 時(shí)間: 2025-3-29 14:29 作者: Occlusion 時(shí)間: 2025-3-29 17:02
Oncoproteomic Approaches to Cancer Marker Discovery: The Case of Colorectal Cancerx-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), quantitative isotopic protein labeling (SILAC, ICAT, and iTRAQ), and two-dimensional gel electrophoresis (2D-PAGE and 2D-DIGE), are being used in cancer research and can improve the diagnosis of patients; they ar作者: 出血 時(shí)間: 2025-3-29 22:01 作者: BOLUS 時(shí)間: 2025-3-30 00:40
MAP17 as Biomarker for Cancer Treatmenterapies increasing ROS and therefore constitute a biomarker for better prognosis of these tumors. In cervix tumors, currently treated with cisplatin and radiotherapy, the presence of MAP17 is a marker for good response to therapy and good survival of the patients. Therefore, MAP17 is not only a mark作者: 朝圣者 時(shí)間: 2025-3-30 07:42
CA 19-9 as a Serum Biomarker in Cancer used most commonly as a biomarker in pancreatic cancer as a prognostic and predictive tool and less commonly in other malignancies. This chapter will focus mainly on utility of CA 19-9 in pancreatic cancer and biliary tract cancers.作者: 神刊 時(shí)間: 2025-3-30 08:45 作者: 細(xì)查 時(shí)間: 2025-3-30 15:59
U2 Small Nuclear RNA as a Biomarker in Cancerd levels among others in the blood of patients suffering from pancreatic, colorectal, and non-small-cell lung cancer as compared to noncancerous controls. Sensitivity and specificity levels reached with the proposed U2 snRNA fragment detection assays were well above the levels reported for current n作者: 姑姑在炫耀 時(shí)間: 2025-3-30 20:36
Centrosome Amplification as Biomarkers in Bladder Cancer Using Touch Biopsy and Bladder Washing Cytoand Ki-67 (MIB-1) overexpression and UroVysion (multicolor fluorescence in situ hybridization kit for detecting copy number aberrations in chromosomes 3, 7, and 17, and the 9p21 locus), are promising for predicting disease progression and tumor recurrence in NMIBC. Further validation with a prospect作者: 格子架 時(shí)間: 2025-3-30 23:08 作者: LEVY 時(shí)間: 2025-3-31 04:04 作者: 疼死我了 時(shí)間: 2025-3-31 08:30 作者: fixed-joint 時(shí)間: 2025-3-31 10:37
OMICS for Tumor Biomarker Researchusually based on genome information. Main sections of OMICS sciences include transcriptomics, proteomics, and metabolomics, powerful research instruments capable of high-throughput detection of biomolecules differentially expressed between tumor and non-tumor samples, including excised tissues or bi作者: affinity 時(shí)間: 2025-3-31 14:24
Circulating Tumor Cells as Biomarkers in Cancericiently sensitive to detect very rare cells, there has been a considerable increase in research to improve detection of CTCs. Here we discuss the current technologies employed for the enumeration and characterization of CTCs. The implementation of such technologies has enabled research into determi
